# NfL and GFAP quantification and associations with mental health in recreational cannabis users-Results from the Swiss study on recreational cannabis access via pharmacies. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-brain-damage-biomarkers-study-neurological-safety-research/ > **Published:** 2026-04-27T13:24:23-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:01:08-04:00 > **Clinical Summary:** New biomarker research on cannabis brain damage biomarkers study results reveals unexpected findings about neurological safety in regular recreational users. --- CED Clinical Relevance  #72Notable Clinical Interest Evidence Brief | CED ClinicBlood biomarkers of neuronal damage show no elevation in recreational cannabis users compared to reference populations, challenging assumptions about cannabis neurotoxicity. NeurotoxicityBiomarkers[Cannabis Safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/)NeuroinflammationCross-Sectional Blood biomarkers of neuronal damage show no elevation in recreational cannabis users compared to reference populations, challenging assumptions about cannabis neurotoxicity. What This Study Teaches Us This study provides the first direct measurement of established neuronal damage biomarkers in recreational cannabis users using highly sensitive assays. The absence of elevated neurofilament light chain and the unexpected reduction in GFAP suggests that regular [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may not produce detectable neuroaxonal damage or astroglial injury at the population level. Why This Matters These findings challenge longstanding concerns about cannabis neurotoxicity that often influence clinical counseling and policy decisions. The data suggest that fears of measurable brain damage from recreational [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) may be overstated, though this requires replication in larger longitudinal studies. Study Snapshot Study Type Cross-sectional observational study Population 331 regular recreational cannabis users from Swiss pharmacy access study Intervention Blood biomarker measurement using ultrasensitive Simoa technology Comparator Age-, BMI-, and sex-adjusted reference populations Primary Outcome Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels Key Finding GFAP levels significantly lower than reference population; NfL levels unchanged Journal Molecular Neurobiology Year 2024 Clinical Bottom Line Regular recreational cannabis users showed no evidence of increased neuronal damage markers compared to non-users, with one marker actually decreased. This provides preliminary reassurance against acute neurotoxicity concerns, though long-term effects and individual vulnerability remain unclear. What This Paper Does Not Show This cross-sectional design cannot establish causality or rule out subtle neurocognitive effects not captured by these biomarkers. The study provides no information about dose-response relationships, duration effects, or outcomes in heavy daily users or adolescent populations. Where This Paper Deserves Skepticism The Swiss cohort may not represent global cannabis user populations, and the reference populations may have unknown cannabis exposure. Cross-sectional design prevents understanding of temporal relationships, and these biomarkers may not capture all forms of cannabis-related brain changes. Dr. Caplan's Take I find these results cautiously reassuring for patients concerned about brain damage from moderate cannabis use. However, I emphasize that absence of these specific damage markers doesn’t guarantee safety for all brain functions, particularly cognitive performance and mental health, which require different assessment approaches. What a Careful Reader Should Take Away This well-conducted biomarker study suggests recreational cannabis use may not cause detectable neuronal damage at the population level. However, this represents just one piece of the neurosafety puzzle and should not be interpreted as comprehensive evidence of [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/) for [brain health](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/). Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20NfL%20and%20GFAP%20quantification%20and%20associations%20with%20mental%20health%20in%20recreational%20cannabis%20users-Resul...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-brain-damage-biomarkers-study-neurological-safety-research%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-brain-damage-biomarkers-study-neurological-safety-research%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20NfL%20and%20GFAP%20quantification%20and%20associations%20with%20mental%20health%20in%20recreational%20cannabis%20users-Resul...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fcannabis-brain-damage-biomarkers-study-neurological-safety-research%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Table of Contents - [FAQ](#FAQ)[Does recreational cannabis use cause measurable brain damage?](#Does_recreational_cannabis_use_cause_measurable_brain_damage) - [What biomarkers can detect cannabis-related brain injury?](#What_biomarkers_can_detect_cannabis-related_brain_injury) - [Should I be concerned about neurotoxicity from regular cannabis use?](#Should_I_be_concerned_about_neurotoxicity_from_regular_cannabis_use) - [How do psychiatric symptoms relate to brain damage markers in cannabis users?](#How_do_psychiatric_symptoms_relate_to_brain_damage_markers_in_cannabis_users) - [Are these findings applicable to all cannabis users?](#Are_these_findings_applicable_to_all_cannabis_users) - [Related](#Related) ## FAQ #### Does recreational cannabis use cause measurable brain damage? This study found no elevation in neurofilament light chain (NfL) levels, a sensitive biomarker for neuroaxonal damage, in recreational cannabis users compared to reference populations. In fact, GFAP levels (indicating astroglial injury) were significantly lower than controls, suggesting cannabis use may not cause detectable neuronal damage at recreational doses. #### What biomarkers can detect cannabis-related brain injury? Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are ultrasensitive blood biomarkers that can detect neuroaxonal damage and astroglial injury, respectively. These biomarkers are measured using single-molecule array (Simoa) technology and are adjusted for age, BMI, and sex to provide accurate assessments of [brain health](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/). #### Should I be concerned about neurotoxicity from regular cannabis use? Based on this study of 331 regular recreational cannabis users, there was no evidence of increased neuronal damage as measured by sensitive blood biomarkers. However, participants with hazardous cannabis use patterns may still be at risk for other health consequences, so moderation remains important. #### How do psychiatric symptoms relate to brain damage markers in cannabis users? The study assessed relationships between NfL/GFAP levels and symptoms of [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/), depression, anxiety, and psychosis in cannabis users. While the complete results aren’t fully detailed in the summary, this approach helps differentiate between functional psychiatric symptoms and actual structural brain damage. #### Are these findings applicable to all cannabis users? This study specifically examined recreational cannabis users in a controlled Swiss pharmacy access program, which may not represent all patterns of cannabis use. Heavy daily users, those using high-THC products, or users with other [substance use disorders](https://cedclinic.com/cannabinoid-clinical-trials-mental-disorders-evidence-2/) may have different risk profiles that weren’t captured in this population. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).